Fig. 3: Validation of correlations of CD27 gene expression with biological and immune features in an independent cohort of 91 metastatic SKCMs from PRJEB23709. | npj Precision Oncology

Fig. 3: Validation of correlations of CD27 gene expression with biological and immune features in an independent cohort of 91 metastatic SKCMs from PRJEB23709.

From: CD27 expression is a clinically accessible biomarker for predicting immunotherapy response in melanoma

Fig. 3: Validation of correlations of CD27 gene expression with biological and immune features in an independent cohort of 91 metastatic SKCMs from PRJEB23709.The alternative text for this image may have been generated using AI.

A Correlation matrix plot shows correlations of CD27 mRNA expression with multiple checkpoint genes. B Box plot showing differences in the absolute proportions of immune cells in the tumor microenvironment between the high and low CD27 mRNA expression groups. C Heatmap displaying the expression of four immune therapy-related signature gene sets, including IFNγ-6, IFNγ expanded immune 18, effector T-cell and IFNγ/effector T-cell. D-G Box plots of gene set enrichment scores of IFNγ-6 (D), IFNγ expanded immune 18 (E), effector T-cell (F) and IFNγ/effector T-cell (G) in high and low CD27 groups of primary melanoma. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, no significance.

Back to article page